Leerink Partnrs Issues Negative Forecast for Geron Earnings

Geron Co. (NASDAQ:GERN) – Analysts at Leerink Partnrs dropped their Q4 2025 earnings per share (EPS) estimates for shares of Geron in a research note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst F. Khurshid now anticipates that the biopharmaceutical company will post earnings of ($0.01) per share for the quarter, down from their prior forecast of $0.02. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share.

Several other equities research analysts also recently weighed in on GERN. HC Wainwright downgraded shares of Geron from a “buy” rating to a “neutral” rating in a report on Wednesday. Barclays reaffirmed an “overweight” rating on shares of Geron in a report on Thursday. Needham & Company LLC boosted their price target on shares of Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Finally, B. Riley lowered shares of Geron from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $3.50 to $2.00 in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $6.77.

Geron Price Performance

NASDAQ GERN opened at $1.61 on Thursday. The company has a 50-day moving average price of $3.00 and a two-hundred day moving average price of $3.81. The stock has a market cap of $973.25 million, a price-to-earnings ratio of -5.03 and a beta of 0.53. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. Geron has a 52 week low of $1.46 and a 52 week high of $5.34.

Geron (NASDAQ:GERN) last announced its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). The company had revenue of $47.54 million during the quarter, compared to the consensus estimate of $45.29 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%.

Hedge Funds Weigh In On Geron

Several institutional investors and hedge funds have recently bought and sold shares of GERN. Creative Planning grew its position in Geron by 23.8% during the third quarter. Creative Planning now owns 92,784 shares of the biopharmaceutical company’s stock valued at $421,000 after purchasing an additional 17,837 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Geron by 23.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 4,094 shares in the last quarter. abrdn plc acquired a new position in Geron in the 3rd quarter worth about $6,752,000. China Universal Asset Management Co. Ltd. raised its position in Geron by 66.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 115,937 shares of the biopharmaceutical company’s stock valued at $526,000 after acquiring an additional 46,254 shares in the last quarter. Finally, US Bancorp DE raised its holdings in shares of Geron by 68.4% during the 3rd quarter. US Bancorp DE now owns 18,296 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 7,429 shares in the last quarter. Hedge funds and other institutional investors own 73.71% of the company’s stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.